Uncommon opportunistic fungi: New nosocomial threats

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 2, 2001, Pages 8-24

  Klont, R R ^a   Meis, J F G M ^b   Verweij, P E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CYCLOSPORIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; RECOMBINANT CYTOKINE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACREMONIUM; ADOPTIVE IMMUNOTHERAPY; ANTIFUNGAL ACTIVITY; CONTROLLED STUDY; DERMATOPHYTE; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; FUSARIUM; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OPPORTUNISTIC INFECTION; PAECILOMYCES; PRIORITY JOURNAL; REVIEW; SCEDOSPORIUM; SCOPULARIOPSIS BREVICAULIS; SPECIES DIFFERENCE; TRICHODERMA; ZYGOMYCETES;

ALTERNARIA; ASPERGILLUS; BIPOLARIS; CANDIDA; CLADOPHIALOPHORA; CLADOPHIALOPHORA BANTIANA; DACTYLARIA; DIPODASCUS; DIPODASCUS CAPITATUS; EXOPHIALA; FUNGI; FUSARIUM; MALASSEZIA; PAECILOMYCES; PSEUDALLESCHERIA; PSEUDALLESCHERIA BOYDII; RHODOTORULA MUCILAGINOSA; SCEDOSPORIUM; SCEDOSPORIUM PROLIFICANS; SCOPULARIOPSIS; SCOPULARIOPSIS BREVICAULIS; TRICHODERMA; ZYGOMYCETES;

EID: 0035747143     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00054.x     Document Type: Article

References (206)

1. The emergence of fungi as major hospital pathogens
2. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
3. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital
4. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
5. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation
6. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
7. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: Diagnosis and therapeutic outcome
8. Emerging fungal pathogens in immunocompromised patients: Classification, diagnosis, and management
9. Uncommon invasive mycoses in AIDS
10. The new fungal opportunists are coming
11. Infection due to Penicillium marneffei, an emerging pathogen: Review of 155 reported cases
12. Mechanisms of resistance to fungal infections
13. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
14. Cryptococcosis
15. Disseminated histoplasmosis in persons infected with human immunodeficiency virus
16. An outbreak of acute pulmonary histoplasmosis among travelers to a bat-inhabited cave in Brazil
17. Histoplasmosis and blastomycosis
18. Cryptococcosis
19. Coccidioidomycosis
20. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake
21. Histoplasmosis. Experience during outbreaks in Indianapolis and review of the literature
22. Current approaches to diagnosis and treatment of fungal infections in children infected with human immunodeficiency virus
23. Endemic mycoses: A treatment update
24. Outbreak of coccidioidomycosis in Washington state residents returning from Mexico
25. Cryptococcus neoformans and cryptococcosis
26. Disseminated infection with Fusarium in recipients of bone marrow transplants
27. Clinical patterns of Fusarium infections in immunocompromised patients
28. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
29. Invasive Fusarium infections: A retrospective survey of 31 cases
30. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: A single institution experience over 10 years
31. The emerging role of Fusarium infections in patients with cancer
32. Anaissie. Taxonomy, biology, and clinical aspects of Fusarium species
33. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology
34. The diagnosis of deep mycoses by morphological methods
35. Polymerase chain reaction and single strand conformational polymorphism (SSCP) for recognition of medically important opportunistic fungi
36. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by
37. Lack of activity of amphotericin B in systemic murine fusarial infection
38. Lipid complex in patients with invasive fungal infections: Analysis of safety and efficacy in 556 cases
39. In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin
40. In vitro activity of voriconazole against selected fungi
41. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi
42. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi
43. Treatment of murine fusariosis with SCH 56592
44. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
45. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species
46. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
47. Diagnosis and successful treatment of fusariosis in the compromised host
48. Fatal disseminated Acremonium strictum infection in a neutropenic host
49. Infection due to the fungus Acremonium (cephalosporium)
50. Acremonium fungemia in two immunocompromised children
51. Acremonium species: New emerging fungal opportunists-in vitro antifungal susceptibilities and review
52. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant patient and a review of human Paecilomyces species infections
53. Paecilomyces lilacinus fungemia in an adult marrow transplant recipient
54. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion
55. Paecilomyces lilacinus catheter-related fungemia in an immunocompromised pediatric patient
56. Hyalohyphomycosis caused by Paecilomyces variotii: A case report, animal pathogenicity and 'in vitro' sensitivity
57. Successful treatment of Paecilomyces variotii infection in a patient with chronic granulomatous disease and a review of Paecilomyces species infections
58. Paecilomyces variotii fungemia in a bone marrow transplant patient
59. Antifungal susceptibilities of Paecilomyces species
60. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
61. Clinical significance of Pseudallescheria boydii: A review of 10 years' experience
62. Central nervous system infection caused by Pseudallescheria boydii: Case report and review
63. Pseudallescheria boydii infection of the central nervous system
64. The epidemiology of pseudallescheriasis complicating transplantation: Nosocomial and community-acquired infection
65. Recurrent Pseudallescheria boydii sinusitis in acute leukemia
66. Infections due to dermatiaceous fungi in organ transplant recipients: Case report and review
67. Pathology of hyalohyphomycosis caused by Scedosporium apiospermum (Pseudallescheria boydii): An emerging mycosis
68. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy
69. Scedosporium apiospermum (Pseudallescheria boydii) infection in a heart transplant recipient: A case of mistaken identity
70. Activity of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii
71. Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
72. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungalagent, against emerging and less-common mold pathogens
73. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
74. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
75. Disseminated infection with Pseudallescheria boydii in a patient with chronic granulomatous disease: Response to gamma-interferon plus antifungal chemotherapy
76. Enhancement of oxidative response and damage caused by neutrophils to Aspergillus fumigatus hyphae by granulocyte colony stimulating factor and interferon-gamma
77. Clinical features of human infection with Scedosporium inflatum
78. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature
79. Disseminated infection by Scedosporium prolificans: An emerging fatality among haematology patients. Case report and review
80. Human phagocytic cell responses to Scedosporium prolificans hyphae
81. In vitro interaction of terbinafine with itraconazole against clinical isolates of Scedosporium prolificans
82. An animal model for invasive infections caused by Scedosporium prolificans
83. Trichoderma pseudokoningii as a cause of fatal infection in a bone marrow transplant recipient
84. Trichoderma longibrachiatum infection in a pediatric patient with aplastic anemia
85. Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: Species identification and review of the literature
86. Molecular identification of human pathogenic Trichoderma isolates of Trichoderma longibrachiatum and Trichoderma citroinviride
87. Trichoderma viride infection in a liver transplant recipient
88. Fatal case of Trichoderma harzianum infection in a renal transplant recipient
89. Recurrent subcutaneous infection due to Scopulariopsis brevicaulis in a liver transplant recipient
90. Invasive Scopulariopsis in the immunocompromised host
91. Invasive hyalohyphomycosis caused by Scopulariopsis brevicaulis in a patient undergoing allogeneic bone marrow transplant
92. Invasive sinonasal disease due to Scopulariopsis candida: Case report and review of scopulariopsosis
93. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
94. Treatment with itraconazole of widespread tinea corporis due to Trichophyton rubrum in a bone marrow transplant recipient
95. Invasive Trichophyton rubrum infection in the immunocompromised host: Report of three cases
96. Primary invasive cutaneous Microsporum canis infections in immunocompromised patients
97. Pharmacology of antifungal compounds
98. An outbreak of tinea corporis in hospital personnel caused by a patient with Trichophyton tonsurans infection
99. Nosocomial transmission of Trichophyton tonsurans tinea corporis in a rehabilitation hospital
100. The ringworm riddle: An outbreak of Microsporum canis in the nursery
101. Developments in phaeohyphomycosis and hyalohyphomycosis
102. Identification of dematiaceous fungi and their role in human disease
103. Phaeohyphomycosis
104. Significance of fungal evolution for the understanding of their pathogenicity, illustrated with agents of phaeohyphomycosis
105. Bipolaris: A serious new fungal pathogen of the paranasal sinus
106. Bipolaris hawaiiensis-caused phaeomycotic orbitopathy. A devastating fungal sinusitis in an apparently immunocompetent host
107. Bipolaris-induced orbital cellulitis
108. Itraconazole treatment of phaeohyphomycosis
109. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
110. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of nine cases and review of the literature
111. Granulomatous encephalitis caused by Bipolaris hawaiiensis
112. Disseminated infection due to Bipolaris australiensis in a young immunocompetent man: Case report and review
113. Phaeohyphomycosis following cardiac surgery: Case report and review of serious infection due to Bipolaris and Exserohilum species
114. Human central nervous system infections due to Xylohypha bantiana (Cladosporium trichoides)
115. Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case
116. Brain abscess caused by Cladosporium trichoides
117. Necrotizing cerebritis in an allogeneic bone marrow transplant recipient due to Cladophialophora bantiana
118. Fatal brain abscesses caused by Ramichloridium obovoideum: Report of three cases
119. U.S. case report of cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (R. mackenziei): Criteria for identification, therapy, and review of other known dematiaceous neurotropic taxa
120. 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichloridium mackenziei')
121. Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient
122. Phaeohyphomycosis caused by Dactylaria (human dactylariosis): Report of a case with review of the literature
123. Nosocomial intravascular infection with Exophiala dermatitidis
124. Catheter-associated fungemia due to Wangiella (Exophiala) dermatitidis
125. Brain abscess caused by Wangiella dermatitidis: Case report
126. Mucormycosis
127. Zygomycetes in human disease
128. Zygomycosis of the respiratory tract
129. Invasive zygomycosis due to Conidiobolus incongruus
130. Zygomycosis in the 1990s in a tertiary-care cancer center
131. Widely disseminated Cunninghamella mucormycosis in an adult renal transplant patient: Case report and review of the literature
132. Disseminated mucormycosis due to Cunninghamella bertholletiae in a liver transplant recipient
133. Cunninghamella bertholletiae infection associated with deferoxamine therapy
134. Burn wound zygomycosis caused by Apophysomyces elegans
135. Zygomycosis due to Mucor circinelloides in a neutropenic patient receiving chemotherapy for acute myelogenous leukemia
136. Infections due to Cunninghamella bertholletiae in patients with cancer: Report of three cases and review
137. Zygomycosis in neonates
138. Cluster of pulmonary infections caused by cunninghamella bertholletiae in immunocompromised patients
139. Mucormycosis association with deferoxamine therapy
140. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
141. Successful treatment of disseminated zygomycosis in a neutropenic patient with amphotericin B lipid complex and granulocyte colony stimulating factor
142. Cutaneous mucormycosis in a heart transplant patient associated with a peripheral catheter
143. Post-traumatic cranial mucormycosis in an immunocompetent patient
144. Disseminated Penicillium marneffei infection in Southeast Asia
145. Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children
146. Penicillium brevicompactum as the cause of a necrotic lung ball in an allogeneic bone marrow transplant recipient
147. Fatal Penicillium citrinum pneumonia with pericarditis in a patient with acute leukemia
148. Penicillium marneffei: An insurgent species among the penicillia
149. Cell-mediated immunity in host resistance against infection caused by Penicillium marneffei
150. Cytokine-induced fungicidal activity of human polymorphonuclear leukocytes against Penicillium marneffei
151. Restriction endonuclease analysis of Penicillium marneffei
152. Case-control study of risk factors for Penicillium marneffei infection in human immunodeficiency virus-infected patients in northern Thailand
153. In vitro antifungal activity of the new triazole D0870 against Penicillium marneffei compared with that of amphotericin B, fluconazole, itraconazole, miconazole and flucytosine
154. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens
155. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients
156. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus
157. Trichosporonosis in patients with neoplastic disease
158. Trichosporon beigelii infection: A review
159. Hematogenous trichosporonosis in cancer patients: Report of 12 cases including 5 during prophylaxis with itraconazole
160. Trichosporon beigelii: A life-threatening pathogen in immunocompromised hosts
161. Azole therapy for trichosporonosis: Clinical evaluation of eight patients, experimental therapy for murine infection, and review
162. Patterns of morphologic variation in strains of Trichosporon beigelii
163. Distinction of deep vs. superficial clinical and non-clinical environmental isolates of Trichosporon beigelii by isoenzymes and RFLP's of rDNA generated by the polymerase chain reaction
164. Contributions to a revision of the genus Trichosporon
165. Infections due to Trichosporon species: New concepts in mycology, pathogenesis, diagnosis, and treatment
166. Trichosporon beigelii: An emerging pathogen resistant to amphotericin B
167. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsular polysaccharide in serum from a patient with disseminated Trichosporon infection
168. Demonstration of a cell wall antigen cross-reacting with cryptococcal polysaccharide in experimental disseminated trichosporonosis
169. Detection and quantification of the glucuronoxylomannan-like polysaccharide antigen from clinical and non-clinical isolates of Trichosporon beigelii: Implications for pathogenicity
170. Response of human polymorphonuclear leukocytes and monocytes to Trichosporon beigelii: Host defense against an emerging pathogen
171. Experimental disseminated trichosporonosis in persistently granulocytopenic rabbits: Implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic infection
172. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B
173. Successful outpatient treatment of Trichosporon beigelii peritonitis with oral fluconazole
174. Blastoschizomyces capitatus: An emerging cause of invasive fungal disease in leukemia patients
175. Disseminated Blastoschizomyces capitatus infection in acute myeloblastic leukaemia. Report of three cases
176. Invasive yeast infections other than Candida spp. in acute leukaemia
177. Blastoschizomyces capitatus infection in acute leukemia patients
178. In-vitro comparative activity of fluconazole and other antifungal agents against Blastoschizomyces capitatus
179. Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients
180. Adjuvant therapy with rhGM-CSF for the treatment of Blastoschizomyces capitatus systemic infection in a patient with acute myeloid leukemia
181. Malassezia furfur
182. Human infections due to Malassezia spp
183. Catheter-related Malassezia furfur fungemia in immunocompromised patients
184. The spectrum of Malassezia infections in the bone marrow transplant population
185. Systemic Malassezia furfur infections in patients receiving intralipid therapy
186. Malassezia fungemia in neonates and adults: Complication of hyperalimentation
187. An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers' pet dogs
188. Malassezia furfur folliculitis in cancer patients. The need for interaction ofmicrobiologist, surgical pathologist, and clinician in facilitating identification by the clinical microbiology laboratory
189. In vitro susceptibility of the seven Malassezia species to ketoconazole, voriconazole, itraconazole and terbinafine
190. Hansenula anomala fungemia
191. Catheter-related fungemia by Hansenula anomala
192. Rhodotorula fungaemia: A life-threatening complication of indwelling central venous catheters
193. New and emerging yeast pathogens
194. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia
195. Invasive infection with Saccharomyces cerevisiae: Report of three cases and review
196. Sepsis due to Rhodotorula related to use of indwelling central venous catheters
197. Hansenula anomala: A new fungal pathogen. Two case reports and a review of the literature
198. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. & Saccharomyces cerevisiae
199. In vitro activity of five antifungal agents against clinical isolates of Saccharomyces cerevisiae
200. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens
201. Lipid formulations of amphotericin B. recent progress and future directions
202. Lipid formulations of amphotericin B. clinical efficacy and toxicities
203. Emerging targets for novel antifungal therapeutics
204. Potential new antifungal agents
205. Lipopeptide inhibitors of fungal glucan synthase
206. The role of immunoreconstitution in the management of refractory opportunistic fungal infections